Biotech – the red-hot, high risk investment story

Heading for default

Turkey will set off the next emerging-market crisis

  • What's behind the car-loan bubble

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

Invest in cutting-edge healthcare

Max King looks at one fund allowing investors to put their money in cutting-edge medical research.

The pharma price-gouging scandal

Pharmaceutical companies have hit the headlines for hiking prices for life-saving drugs by shocking amounts. What’s going on? Simon Wilson reports.

The race to commercialise our DNA

The race to development and sell gene-editing procedures will be as exciting as the race into space, says Nick O’Connor.

Three promising sectors for 2017

Max King tips a host of funds in various sectors to do well in the forthcoming year.

Lilly fails Alzheimer’s test

Eli Lilly’s new treatment has proved ineffective in late-stage trials – yet another blow for a struggling sector, says Ben Judge.

Who will prosper under Trump?

Now that the markets have got over the shock of a Trump victory in the US presidential election, David C Stevenson looks at which funds to buy.

Earn a 3.5% yield from healthcare

David C Stevenson looks at the best healthcare and biotech investment trusts to tuck away in your portfolio.

Novo Nordisk: Pharma giant takes a tumble

Novo Nordisk shocked investors by slashing its growth forecasts. The new CEO faces a tough start, says Ben Judge.

Neoevolution with gene-editing

Gene-editing puts mankind in control of its own evolution. People are going to become increasingly creative with this technology, says Nick O’Connor.

The wrath of man

Mankind continues to push back the boundaries of what is medically possible, says Nick O’Connor. It is quite possibly the greatest undertaking in human history.

Showing page 1 of 2
Merryn

Claim 12 issues of MoneyWeek (plus much more) for just £12!

Let MoneyWeek show you how to profit, whatever the outcome of the upcoming general election.

Start your no-obligation trial today and get up to speed on:

  • The latest shifts in the economy…
  • The ongoing Brexit negotiations…
  • The new tax rules…
  • Trump’s protectionist policies…

Plus lots more.

We’ll show you what it all means for your money.

Plus, the moment you begin your trial, we’ll rush you over THREE free investment reports:

‘How to escape the most hated tax in Britain’: Inheritance tax hits many unsuspecting families. Our report tells how to pass on up to £2m of your money to your family without the taxman getting a look in.

‘How to profit from a Trump presidency’: The election of Donald Trump was a watershed moment for the US economy. This report details the sectors our analysts think will boom from Trump’s premiership, and gives specific investments you can buy to profit.

‘Best shares to watch in 2017’: Includes the transcript from our roundtable panel of investment professionals – and 12 tips they’re currently tipping. The report also analyses key assets, including property, oil and the countries whose stock markets currently offer the most value.